Indivior PLC INDV

NAS: INDV | ISIN: GB00BN4HT335 10/10/2025

23,78 USD (-1,53%)

(-1,53%) 10/10/2025

Grafiek Indivior PLC

Grafiek Indivior PLC

1 dag1d -1,53%
1 week1w 4,62%
1 maand1m 2,52%
3 maanden3m 52,24%
6 maanden6m 151,91%
1 jaar1j 201,01%
5 jaar5j 3,89%

Indivior PLC in het nieuws

Toon enkel gratis nieuws

1 oktober 2025 · Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation · Persbericht

20 augustus 2025 · Indivior to Participate in Upcoming Investor Events · Persbericht

31 juli 2025 · Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance · Persbericht

25 juli 2025 · Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained · Persbericht

23 juli 2025 · Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder · Persbericht

17 juli 2025 · Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st · Persbericht

8 juli 2025 · Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs · Persbericht

30 juni 2025 · Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes · Persbericht

24 juni 2025 · Indivior Appoints Tony Kingsley to the Board of Directors · Persbericht

19 juni 2025 · Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users · Persbericht

Profiel Indivior PLC

Farmaceutische producten: Andere

Gezondheidstechnologie

Medicinale en botanische productie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe